United States Patent 5,811,423: Scope of Claims, Combination-Method Boundaries, and US Landscape
US Patent 5,811,423 claims combination-treatment methods for HIV infection, AIDS, or ARC, built around administration of a Formula I (and related Formula) compound alongside specified anti-HIV agents. The claims are drafted as method-of-treatment claims that include both (i) a structural definition for the key compound(s) and (ii) drug-class level limitations for co-administered therapies (AIDS antivirals, immunomodulators, antiinfectives, vaccines, HIV protease inhibitors, and nucleoside reverse transcriptase inhibitors (NRTIs)).
What the claims cover (high-level)
- Monotherapy structure tied to disease indication: claims that administer a compound of Formula I to treat HIV infection / AIDS / ARC.
- Combination therapy methods: claims that administer the Formula I compound plus one or more agents from a recited group, including HIV protease inhibitors and NRTIs.
- Formulation of “optionality” across related claims: later claims narrow by requiring specific co-agents (including combinations of protease inhibitor + nucleoside analog).
- A “two-drug” dependent claim: claim 6 specifically requires Formula compound + HIV protease inhibitor + nucleoside analog.
1. What is the claim anchor: Formula I structural definition?
Claim 1 and dependent claim structure repeatedly define a Formula I compound using a variable set:
- X is halo
- X1 is trihalomethyl or pentahaloethyl
- Z is O
- R is selected from sub-classes (a) to (d):
- (a) C1-8 alkyl (unsubstituted or substituted with A), where A is one of:
- halo
- C3-6 cycloalkyl
- CN
- hydroxy
- C1-4 alkoxy
- C2-4 alkynyl-C1-4 alkoxy
- aryloxy
- C1-4 alkylcarbonyl
- nitro
- di(C1-2 alkyl)amino
- C1-4 alkylamino-C1-2 alkyl
- heterocycle
- arylthio
- (b) C2-4 alkenyl (unsubstituted or substituted with)
- (i) A, or
- (ii) aryl (unsubstituted or substituted with A)
- (c) C2-5 alkynyl (unsubstituted or substituted with)
- (i) A, or
- (ii) aryl (unsubstituted or substituted with A)
- (d) C3-4 cycloalkyl (unsubstituted or substituted with)
- (i) A, or
- (ii) aryl (unsubstituted or substituted with A)
Practical implication for infringement and design-around
The structural boundaries are broad at the substituent-definition level. The variables allow wide latitude for substitution via A and via aryl/alkenyl/alkynyl substituent paths.
From a claim-scoping perspective, the key gating issue is whether a product’s active matches the allowed variable set (X halo; X1 trihalomethyl or pentahaloethyl; Z = O; R within defined ranges, with allowed substituents). The co-therapy agent selection is comparatively easier to satisfy because the claim recites drug-class level categories.
2. What do claims 1–6 require, in operational terms?
Claim 1 (combination-inclusive, Formula I + at least one of listed agent types)
Claim 1 requires:
- administering to a mammal an effective amount of a Formula I compound; and
- one or more agent selected from:
- an AIDS antiviral
- an immunomodulator
- an antiinfective
- a vaccine
- an HIV protease inhibitor
- a nucleoside analog having biological activity against HIV reverse transcriptase
Coverage boundary: includes both add-on therapies and treatment regimens where the Formula I compound is paired with at least one agent in the enumerated group.
Claim 2 (Formula compound of a related Formula + at least one agent)
Claim 2 requires:
- administering a compound of another defined Formula (Formula recited as ##STR83## in the text you provided); and
- one or more agent from the same enumerated group as claim 1.
Impact: this extends the method claims to a related structural set, likely reflecting alternative embodiments in the patent’s chemistry.
Claim 3 (Formula I + HIV protease inhibitor + optional nucleoside analog)
Claim 3 requires:
- Formula I compound
- an HIV protease inhibitor
- optionally a nucleoside analog (and/or its pharmaceutically acceptable salt)
Claim 4 (Formula I + nucleoside analog; optional protease inhibitor)
Claim 4 requires:
- Formula I compound
- a nucleoside analog (and optionally an HIV protease inhibitor)
Claim 5 (Formula I + protease inhibitor + required nucleoside analog)
Claim 5 requires:
- Formula I compound
- an HIV protease inhibitor
- and a nucleoside analog (not optional)
Claim 6 (dependent claim: Formula compound + protease inhibitor + nucleoside analog)
Claim 6 states the method as in claim 4 comprising:
- administering to a mammal an effective amount of a Formula compound; and
- a HIV protease inhibitor, and
- a nucleoside analog (or salts)
Key difference from claim 5: claim 6 ties itself to the structure of claim 4 (nucleoside analog core), but it still results in a required triple element: Formula compound + protease inhibitor + nucleoside analog.
3. How broad are these method claims as a combination-treatment patent?
3.1 Agent category breadth (high)
The listed co-therapies are not limited to a single named product. They include:
- HIV protease inhibitor (category)
- nucleoside analog active against HIV reverse transcriptase (category)
- AIDS antiviral, immunomodulator, antiinfective, vaccine (category-level)
This makes the claims regimen-flexible: a practitioner could select among multiple anti-HIV or supportive agents and still fall inside “one or more agents” coverage (claim 1 and claim 2).
3.2 Optionality creates overlapping scopes
Claims 3–5 carve the regimen space with different required/optional elements:
- Claim 3: protease inhibitor required; nucleoside optional
- Claim 4: nucleoside required; protease inhibitor optional
- Claim 5: both required
This structure expands enforceability by targeting multiple likely treatment combinations and giving the patentee fallback positions depending on which components a defendant uses.
3.3 Disease indication is fixed but common
All methods use the same indication set:
- treating infection by HIV
- treating AIDS or ARC
This restricts the methods to HIV-AIDS contexts, but those contexts are the core markets for anti-retroviral regimens.
4. Claim construction hotspots for litigation and freedom-to-operate
4.1 “Effective amount” and “administering” (method mechanics)
These are standard method-of-treatment phrasing. In practice, the claim likely covers:
- any regimen where the Formula compound and the specified co-agent are administered as part of treatment for the claimed indication.
4.2 “One or more agent” (claims 1–2)
“one or more agent” means infringement risk persists even for minimal combination regimens using only:
- a protease inhibitor, or
- a nucleoside analog, or
- another agent category enumerated.
4.3 Pharmaceutically acceptable salts
Claims 3–6 incorporate salts as covered alternatives. This matters for typical salt-form variants of NRTIs and protease inhibitors, and for any salt form of the Formula compound if the chemistry supports it.
4.4 Formula compliance is the gating element
Because the Formula is the anchor, the largest FTO risk driver is the chemical variable match:
- specific halogen patterns (X halo; X1 tri/penta-halogenated methyl/ethyl analog)
- Z = O
- R substructure limits (C1-8 alkyl or C2-4 alkenyl or C2-5 alkynyl or C3-4 cycloalkyl, with substituent A or aryl substitution patterns)
A design-around that changes the core variable definitions is likely to be necessary to leave the literal scope.
5. Patent landscape: US coverage structure and likely adjacent claim clusters
You asked for a “patent landscape,” but the only concrete artifact provided is the US patent number and claim text. Without bibliographic details (filing/publication family, assignee, and cited references), the landscape analysis can only be structured at a claim-typology level based on how US patents like 5,811,423 are generally positioned.
5.1 Landscape by claim typology (most relevant to 5,811,423)
US combination patents in HIV historically split into three overlapping enforcement lanes:
-
Core compound composition / analog claims
- protect specific chemical entities (and often salts, solvates, polymorphs)
-
Method-of-treatment claims for disease indications
- protect specific therapeutic uses and dosing/regimen frameworks
-
Combination regimen claims
- protect co-administration with one or more drug classes (protease inhibitors, NRTIs, NNRTIs, immunomodulators, etc.)
US 5,811,423 is squarely in lane 3, with lane 2 partially embedded via disease indication and lane 1 embedded via a structural Formula.
5.2 Likely competitive impact zones (where enforcement typically bites)
Given the agent list includes:
- HIV protease inhibitors
- nucleoside analogs against reverse transcriptase
The enforcement bite concentrates on regimens that use:
- protease inhibitor-based combinations, and/or
- nucleoside-based combinations
The presence of optionality in claims 3 and 4 broadens the set of regimens a defendant cannot easily avoid by switching between “protease-required” vs “nucleoside-required” embodiments.
5.3 What a “nucleoside analog” limitation implies
“Nucleoside analog having biological activity against HIV reverse transcriptase” is broad enough to capture multiple NRTIs (and likely their prodrugs where reverse transcriptase activity derives from the active metabolite). For freedom-to-operate, the key is whether the product regimen uses any drug that meets that functional category.
6. Scope map: how each claim narrows or expands enforceability
| Claim |
Formula requirement |
Co-agent requirement |
Optional co-agent |
Net regimen coverage |
| 1 |
Formula I |
“one or more agent” from enumerated group incl. protease inhibitor and NRT |
none stated |
broadest combo basket |
| 2 |
related Formula (##STR83##) |
“one or more agent” from same enumerated group |
none stated |
broadest combo basket for related structure |
| 3 |
Formula I |
HIV protease inhibitor |
nucleoside analog optional |
protease-centric regimens |
| 4 |
Formula I |
nucleoside analog required |
protease inhibitor optional |
nucleoside-centric regimens |
| 5 |
Formula I |
protease inhibitor required + nucleoside required |
none |
tight double-combo regimens |
| 6 |
(as in claim 4) Formula compound |
protease inhibitor + nucleoside analog required |
none |
narrowest three-element method |
7. Business-useful takeaways for R&D and investment diligence
7.1 What to diligence first
- Chemical match to the variable set defining Formula I (X, X1, Z, R, and A substituents).
- Regimen match to whether the co-administered therapy fits:
- “HIV protease inhibitor” and/or
- “nucleoside analog … against HIV reverse transcriptase”
- Combination ordering and timing is often less determinative than whether the method results from “administering” the combination for the claimed indication. If the regimen includes both elements, claims 3–6 are at risk.
7.2 Where this patent most likely creates value
The combination method claims tend to increase leverage when:
- multiple HIV drug classes are used together in clinical practice, and
- the Formula compound is positioned as the added agent across common regimens.
Claims 1 and 2 are especially leverage-bearing because the agent list is not limited to just protease inhibitors and nucleosides; it includes immunomodulators and vaccines.
7.3 Where design-around is most plausible
A credible exit from scope generally requires:
- changing the Formula-defined structure variables such that Formula I is not met (X/X1/Z/R/A changes), rather than relying solely on switching between protease inhibitor vs nucleoside analog combinations, because claims 3–5 cover both directionality and claim 5 covers the “both required” case.
Key Takeaways
- US 5,811,423 is a regimen-enforcement patent: it claims HIV/AIDS/ARC treatment methods combining a Formula I (and related Formula) compound with co-administered HIV agent classes, including HIV protease inhibitors and reverse transcriptase-active nucleoside analogs.
- Claims 1 and 2 are the broadest by requiring Formula compound administration plus “one or more” from a wide enumerated co-agent group.
- Claims 3–5 and claim 6 narrow the co-therapy matrix through required vs optional protease/nucleoside combinations, but still leave substantial regimen overlap.
- The dominant FTO risk driver is structural compliance with the Formula I definitions (X, X1, Z, R, A). Regimen changes alone are unlikely to fully avoid risk if any included protease inhibitor and nucleoside analog are used in the claimed therapeutic context.
FAQs
1) Does US 5,811,423 require both a protease inhibitor and an NRTI in all claims?
No. Claims 1–2 require Formula compound plus one or more co-agent from the enumerated group. Claim 3 requires a protease inhibitor with nucleoside optional; claim 4 requires a nucleoside analog with protease optional. Claims 5–6 require both.
2) What co-therapy categories are explicitly included beyond standard antiretrovirals?
The claims include AIDS antivirals, immunomodulators, antiinfectives, and vaccines, in addition to HIV protease inhibitors and nucleoside analogs active against HIV reverse transcriptase (claims 1–2).
3) How is “nucleoside analog” defined in the claims?
It is defined by functional biological activity: “having biological activity against HIV reverse transcriptase,” not by a named chemical.
4) Is the disease limitation limited to HIV infection broadly, or only AIDS?
The method claims cover HIV infection, and also AIDS or ARC.
5) What is the most important structural feature to clear for design-around?
The set of Formula I variables, particularly X (halo), X1 (trihalomethyl or pentahaloethyl), Z (O), and the R substituent range with A substituents, must be avoided if you intend to exit literal scope.
References
[1] US Patent 5,811,423, claims 1–6 (as provided in the prompt text).
